Clinical trials: Cytomegaloviral Infection
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cytomegalovirus Infections
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
- Trial name
- NCT04478474
- Testing
- Ganciclovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York Medical College
Cytomegalovirus Infections
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Many risk factors are known to be associated with high risk of developing CMV infection in positive CMV-serostatus patients: negative CMV-serostatus donor, unrelated or mismatched donor, use of antithymocyte globulin (ATG), and…
- Trial name
- CMV-GVHD (NCT05370976)
- Testing
- Cytotect®CP
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Lille
Cytomegalovirus Retinitis, Acute Renal Failure
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro studies.
- Trial name
- NCT01866397
- Testing
- Cidofovir pharmacokinetics
- Where
- Austria
- Volunteers
- 1 people
- Sponsor
- Medical University of Vienna
CMV, Lung Transplant Recipient
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant…
- Trial name
- CLEAR-CMV (NCT07235683)
- Testing
- Letermovir, Valganciclovir/Ganciclovir
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection
Study of Prophylactic Vs Preemptive Valganciclovir
This is a study of prophylactic Vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients looking at clinical and pharmacoeconomic outcomes
- Trial name
- NCT00374686
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Retinitis, HIV Infections
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in…
- Trial name
- NCT00000894
- Testing
- Cidofovir, Probenecid, Ganciclovir
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Congenital CMV Infection
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of pediatric hearing loss and an important cause of neurodevelopmental delay.
- Trial name
- NCT02680743
- Testing
- Education of parents to pursue prompt hearing screening.
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
Cytomegalovirus Infections
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection
OBJECTIVES: I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.
- Trial name
- NCT00004278
- Testing
- ganciclovir
- Volunteers
- 130 people
- Sponsor
- National Center for Research Resources (NCRR)
Cytomegalovirus Infection
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus (CMV) infection is known to cause hearing loss and mental retardation. The purpose of this study is to compare a 6-week course to a 6-month course of the drug valganciclovir in babies born with CMV to assess the…
- Trial name
- NCT00466817
- Testing
- Valganciclovir
- Where
- 48 sites in United States, United Kingdom
- Volunteers
- 109 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT06059391
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor
- Where
- 3 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202…
- Trial name
- NCT04975893
- Testing
- mRNA-1647
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- ModernaTX, Inc.
HIV Infections, Acquired Immunodeficiency Syndrome
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed.
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- CRRT (NCT00000134)
- Testing
- Ganciclovir, Foscarnet
- Volunteers
- 279 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cytomegalovirus Congenital Infection
Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Because the potential benefit of standard intravenous immunoglobulins (IVIG) - obtained from unselected donor pools including a varying proportion of donors previously exposed to CMV - has not yet been explored in pregnant women…
- Trial name
- NCT01659684
- Testing
- standard intravenous immunoglobulin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Onlus Camillo De Lellis
CMV
Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients…
- Trial name
- NCT04392297
- Testing
- Bood leukocyte subsets, CMV specific T-cells, serum CMV IgM / IgG antibodies
- Where
- Belarus
- Volunteers
- 45 people
- Sponsor
- The Republican Research and Practical Center for Epidemiology and Microbiology
Kidney Transplant Infection
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.
In kidney transplant patients, CMV infection remains the leading infectious cause of morbidity and mortality. Clinical and virological relapses are common and are involved in chronic graft dysfunction.
- Trial name
- SPARCKLING (NCT03339661)
- Testing
- Group 1_No proph treatment, Group 2A_Proph treatment and γδ T cell expansion, Group 2B_Proph treatment and no γδ T cell expansion
- Where
- 2 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Lung Transplant
PREDICT Cytomegalovirus (CMV)
The overall objective of this study is to establish a personalized test to measure individualized cytomegalovirus (CMV) specific immunity in lung transplant recipients in an effort to guide antiviral prophylaxis duration in…
- Trial name
- PREDICT CMV (NCT03300882)
- Testing
- Procedure
- Where
- 4 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections, HIV Infections
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.
- Trial name
- NCT00002024
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche